Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include HiSeq 2000, an instrument for high-throughput (up to 200 Gb per run and up to 25 GB per day) sequencing using sequencing-by-synthesis (SBS) technology; Genome Analyzer IIx, an instrument for medium to high-throughput (up to 95 Gb per run) sequencing using SBS technology; Genome Analyzer IIe, an instrument for low to medium throughput (up to 40 Gb per run) sequencing using SBS technology; iScan System, a high-resolution imaging instrument to scan BeadArray based assays; and BeadXpress Reader, a low- to mid-multiplex, high-throughput instrument for readout of assays. The company?s consumables consist of InfiniumHD Whole-Genome BeadChips comprising HumanOmniExpress, HumanOmni1-Quad, Human1M-Duo, and BovineHD, which are multi-sample DNA analysis microarrays; iSelect Custom Genotyping BeadChips that are custome r designable SNP genotyping arrays; GoldenGate Assay Method, a high throughput assay and genotyping system; GoldenGate Universal-32 Sample BeadChip, which are 32 sample GoldenGate genotyping arrays; Paired-End Genomic DNA Sample Prep Kit, a streamlined library preparation kit to generate 200?500 kb insert paired-end reads; VeraCode GoldenGate that are low plex GoldenGate genotyping arrays compatible with the BeadXpress System; Standard Sequencing Kit, reagents used for SBS chemistry on sequencing platforms; and Infinium Assay Kit, reagents used to perform Infinium assays on the iScan platform. It also provides sequencing and genotyping services. The company?s customers include pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as research centers. It sells its products through distributors in North America, Europe, the Asia-Pacific, the Middle East, and South Africa. Illumina was founded in 1998 and is headquartered in San Dieg o, California.
News about ILMN
Week In Review: Human Gene Editing Scandal Revisited; Can China Biopharma Continue To Expand? News O
Industry Insights In a deeply researched Wall Street Journal article, Preetika Rana provides extraordinary depth into the story of Dr. Jiankui He, the man who announced last November he had used Crispr-Cas9 gene editing to alter human embryos in eigh...Read More>>>
5 Stocks in the Age of Miracles
Every so often on Rule Breaker Investing, Motley Fool co-founder David Gardner shares a five-stock sampler -- five active recommendations in either Rule Breakers or Stock Advisor that are poised for great things. This week: five healthcare companies ...Read More>>>
Is iShares Nasdaq Biotechnology Index Fund a Buy?
The biotechnology industry is one of the most hazardous places for stock pickers. Volatility is high, even among the largest companies. Creating new compounds and processes that solve complicated medical problems is not an easy business, and there'...Read More>>>
Is Illumina a Buy?
No company has dominated gene sequencing like Illumina (NASDAQ:ILMN). And the stock's performance has reflected that dominance. Illumina's share price has skyrocketed more than 850% over the past 10 years. Success isn't just a thing of the past for...Read More>>>
AlphaCrest Capital Management LLC Invests $300,000 in Illumina, Inc. (ILMN)
AlphaCrest Capital Management LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,000 sh...Read More>>>